However, with appropriate monitoring and clinical intervention, many of the adverse effects seen with mTOR inhibitors are manageable; for example, the dyslipidemia that occurs with mTOR inhibitors can be managed with lipid-lowering drugs, and mouth ulcers can be effectively treated with topical kenalog-in-orabase. This evidence concerns the gene MTOR and Oral ulcer.